CMS grants Medicare add-on payment status to Omeros's TA-TMA drug

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to CMS grants Medicare add-on payment status to Omeros's TA-TMA drug

CMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA®

August 3, 2026 8:30 AM EDT

--Provides additional Medicare reimbursement to hospitals and supports patient access for eligible Medicare patients with TA-TMA--

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (Nasdaq: OMER) today announced that the Centers for Medicare & Medicaid Services (CMS) has granted New Technology Add-On Payment (NTAP) status for YARTEMLEA® (narsoplimab-wuug) under the Fiscal Year (FY) 2027 Hospital Inpatient Prospective Payment System (IPPS) Final Rule. Beginning October 1, 2026, eligible hospitals treating Medicare patients with YARTEMLEA for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) will receive additional Medicare reimbursement. YARTEMLEA is the first and only FDA-approved treatment for TA-TMA, a rare,... More